Programme

Hotel Opera, 30 November 2006

    Moderator: Knut Haanes
 

0830-0900

Welcome
by Jørgen Smith, Director General, The Norwegian Patent Office
 

PART 1:

International Experiences and Trends

Current and Future Opportunities and Challenges in the Biotech Industry
by Ms. Bénédicte Callan, Prinicipal Administrator, Biotechnology Division, OECD
 

Developing A Patent System To Strengthen European Biotech Industry’s Position
by Ingwer Koch, Director and Head of Patent Law, European Patent Office (EPO)
 

Establishing the Size of the Opportunity: How Much is Patentable in the Biotech Field?
by Philip Webber, Partner, Frank B. Dehn & Co.
 

Fostering Finance on the Basis of IP: Crucial for Innovation
by Dr. Roya Ghafele, Economist Life Sciences Program, WIPO
 

The Process of Taking a Norwegian Biotechnology Company into the U.S. market
by Paul Fehlner, partner, Baker Botts L.L.P.
 

PART 2:

From Research to Commercialization

IP for Bioscience Start-Ups: Spending your Investors' Money Wisely
by Andrew G. Sheard, Patent Attorney
 

From Idea to Worldwide Success
by Hans-Axel Hansson, inventor and founder, DiLab
 

Technology Transfer and Commercialization – a New Approach to Seed Investments
by Conny Bogentoft, Vice President, Karolinska Institutet Holding AB
 

 PART 3:

(This session will be held in Norwegian)

Moderator for Part 3: Thomas Grünfeld

Investeringskapital og såkornfond

Nasjonale og regionale såkornfond
v/ Stein Jodal, spesialrådgiver, Innovasjon Norge
 

Sarsia Seed  - nytt såkornfond innen life-science og energi
v/  Øivind Enger, analytiker, Sarsia Seed
 

Viktige suksessfaktorer for biotekbransjen
v/ Jens Petter Falck, partner, Selvaag Venture Capital
 

Plenumsdiskusjon:
Investering i norsk bioteknologi
- hvor er viljen?
- hvor er kunnskapen?